active folate
PreclinicalSmall molecule
active folate is one of 19 small molecule programs targeting Type 1 Diabetes. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
18
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
384 competitors in Type 1 Diabetes
#DrugCompanyPhaseTrials
1Symlin
AstraZenecaPreclinical
Aldomet
Neurocrine BiosciencesPreclinical
Glargine
Eli LillyPreclinical
Pitocin
RRetrophin
Preclinical
Feraheme
AAzurity Pharmaceuticals
Preclinical
Cytoxan
BBaxter Healthcare Corporation
Preclinical
Foradil
ViatrisPreclinical
SGLT2 Inhibitor
Eli LillyPreclinical
Teplizumab
SanofiPreclinical
Mesenchymal Stem Cells
JJiangsu Topcel-KH Pharmaceutical Co., Ltd.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for active folate. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- SShanghai Changzheng Hospital